Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy

Table 1 Demographic characteristics, clinical and laboratory findings of patients with 5-aminosalicylate withdrawal, n (%)

Characteristics	Total (n = 30)
Age at onset of IBD (years), median (IQR)	31.0 (22.0-36.0)
Female/male	13 (43.3)/17 (56.7)
Smoking status (current/ex/non-smokers)	7/8/15
Family history of IBD	6 (20.0)
BMI (kg/m2), median (IQR)	23.5 (20.6-27.5)
Total disease duration (months), median (IQR)	175.0 (86.0-254.3)
Duration of remission before 5-ASA withdrawal (months), median (IQR)	140.5 (20.3-192.3)
Follow-up time from 5-ASA withdrawal (months), median (IQR)	26.0 (16.8-65.0)
Disease extension
Proctitis	6 (20.0)
Left-sided UC	21 (70.0)
Extensive UC	3 (10.0)
Extra-intestinal manifestations	14 (46.7)
Prior medications
5-ASA tablet	25 (83.3)
5-ASA granule	2 (6.7)
5-ASA enema	28 (93.3)
5-ASA suppository	5 (16.7)
Sulfasalazine	1 (3.3)
Steroids	9 (30.0)
Thiopurine	3 (10.0)
Adalimumab	0 (0.0)
Infliximab	2 (6.7)
Vedolizumab	0 (0.0)
Ustekinumab	0 (0.0)
Steroid dependence	3 (10.0)
Withdrawal 5-ASA formula
5-ASA tablet	25 (83.3)
5-ASA granule	2 (6.7)
5-ASA enema	18 (60.0)
5-ASA suppository	6 (20.0)
Relapse	12 (40.0)
Baseline CRP (mg/L), median (IQR)	5.0 (5.0-5.0)
Baseline hemoglobin (g/dL), median (IQR)	13.0 (12.0-13.0)
Baseline albumin (g/dL), median (IQR)	4.0 (4.0-4.2)
Baseline eMayo subscore, median (IQR)	1.0 (1.0-1.3)
Baseline pMayo score, median (IQR)	5.0 (5.0-5.0)

Data presented as ‘baseline’ represent ‘at the time of initial diagnosis’. IBD: Inflammatory bowel disease; IQR: Interquartile range; BMI: Body mass index; UC: Ulcerative colitis; CRP: C-reactive protein; 5-ASA: 5-aminosalicylates; eMayo: Endoscopic Mayo subscore; pMayo: Partial Mayo score.